Jo Junyoung, Leem Jungtae, Lee Jin Moo, Park Kyoung Sun
Department of Korean Medicine Obstetrics and Gynecology, Conmaul Hospital of Korean Medicine, Seoul, South Korea.
Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine Hospital, Seoul, South Korea.
BMJ Open. 2017 Jun 15;7(6):e015056. doi: 10.1136/bmjopen-2016-015056.
Primary dysmenorrhoea is menstrual pain without pelvic pathology and is the most common gynaecological condition in women. Xuefu Zhuyudecoction (XZD) or Hyeolbuchukeo-tang, a traditional herbal formula, has been used as a treatment for primary dysmenorrhoea. The purpose of this study is to assess the current published evidence regarding XZD as treatment for primary dysmenorrhoea.
The following databases will be searched from their inception until April 2017: MEDLINE (via PubMed), Allied and Complementary Medicine Database (AMED), EMBASE, The Cochrane Library, six Korean medical databases (Korean Studies Information Service System, DBPia, Oriental Medicine Advanced Searching Integrated System, Research Information Service System, Korea Med and the Korean Traditional Knowledge Portal), three Chinese medical databases (China National Knowledge Infrastructure (CNKI), Wan Fang Database and Chinese Scientific Journals Database (VIP)) and one Japanese medical database (CiNii). Randomised clinical trials (RCTs) that will be included in this systematic review comprise those that used XZD or modified XZD. The control groups in the RCTs include no treatment, placebo, conventional medication or other treatments. Trials testing XZD as an adjunct to other treatments and studies where the control group received the same treatment as the intervention group will be also included. Data extraction and risk of bias assessments will be performed by two independent reviewers. The risk of bias will be assessed with the Cochrane risk of bias tool. All statistical analyses will be conducted using Review Manager software (RevMan V.5.3.0).
This systematic review will be published in a peer-reviewed journal. The review will also be disseminated electronically and in print. The review will benefit patients and practitioners in the fields of traditional and conventional medicine.
CRD42016050447.
原发性痛经是指无盆腔病变的经期疼痛,是女性最常见的妇科病症。血府逐瘀汤(XZD),即血府逐瘀汤,是一种传统中药方剂,已被用于治疗原发性痛经。本研究的目的是评估目前已发表的有关血府逐瘀汤治疗原发性痛经的证据。
将检索以下数据库自建库起至2017年4月的数据:医学文献数据库(通过PubMed)、综合与补充医学数据库(AMED)、EMBASE、考克兰图书馆、六个韩国医学数据库(韩国研究信息服务系统、DBpia、东方医学高级检索集成系统、研究信息服务系统、韩国医学数据库和韩国传统知识门户)、三个中国医学数据库(中国知网、万方数据库和中文科技期刊数据库(维普))以及一个日本医学数据库(CiNii)。本系统评价纳入的随机临床试验(RCT)包括使用血府逐瘀汤或改良血府逐瘀汤的试验。RCT中的对照组包括不治疗、安慰剂、传统药物或其他治疗。测试血府逐瘀汤作为其他治疗辅助手段的试验以及对照组与干预组接受相同治疗的研究也将纳入。数据提取和偏倚风险评估将由两名独立的评审员进行。偏倚风险将使用考克兰偏倚风险工具进行评估。所有统计分析将使用Review Manager软件(RevMan V.5.3.0)进行。
本系统评价将发表在同行评审期刊上。该评价还将以电子和印刷形式传播。该评价将使传统医学和常规医学领域的患者和从业者受益。
PROSPERO注册号:CRD42016050447。